ClinicalTrials.gov
public full text
Public Domain
Positron Emission Tomography - Computed Tomography (PET-CT) Cetuximab Project
Molecular imaging with positron emission tomography (PET) using \[18F\] fluorodeoxyglucose (FDG) has been suggested as an early, sensitive marker of tumour response to anticancer drugs by monitoring the changes in glucose metabolism in tumours. Recently, FDG-PET has shown to be highly sensitive in detecting early response in other tumours. In this study, the investigators will prospectively investigate the role of early FDG-PET (at day 7 and week 6) in outcome prediction.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence#843616
- 18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology#912542
- Cardiac FDG PET Viability Registry#802028
- Prognostic value of pre-therapeutic FDG-PET radiomic analysis in gastro-esophageal junction cancer#971268
- FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma#848906
Record · ID 800570
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive